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CASE PRESENTATIONS
Patient 1. A 49-year-old man reported recurrent episodes of arthralgia,
purpura, and abdominal colic over 2 years. He was transferred to the San
Carlo Hospital in Milan from another hospital, where he had been
admitted because of fever, abdominal pain, purpura and edema of the
legs, slightly increased serum creatinine (1.5 mg/dl), nephrotic-range
proteinuria (4–5 g/day), and positive serum cryoglobulins (cryocrit 1%).
On admission to San Carlo Hospital, the proteinuria was still in the
nephrotic range, with reduced total serum proteins (4.9 g/dl), and the
cryocrit was 11%, with mixed cryoglobulins characterized as IgG-IgMk.
Serum C4 was almost undetectable, with C3 moderately reduced; ALT
was 57 U/liter. Hepatomegaly was present, and a liver biopsy disclosed
mild active chronic hepatitis. Markers for HBV were negative, while
anti-HCV antibodies were detected a posteriori in the stored serum. His
blood pressure was markedly elevated, and severe retinal lesions (grade 3
hypertensive retinopathy) were present.
Within a few days after admission, the serum creatinine level increased
to 3.9 mg/dl. A percutaneous renal biopsy containing 17 glomeruli showed
marked endocapillary hypercellularity characterized by mesangial cell
proliferation and intense infiltration of leukocytes (Fig. 1A), mainly a
massive accumulation of monocytes/macrophages; these findings were
confirmed by an immunohistochemical study (Fig. 1B). Diffuse thickening
of the glomerular basement membrane, with a double contour appear-
ance, also was present. All glomeruli contained amorphous, eosinophilic,
PAS-positive deposits totally filling the capillary lumina (“intraluminal
thrombi”) (Fig. 1A). Segmental subendothelial deposits also were present.
The interstitium was diffusely edematous, with tubular atrophy and mild
diffuse leukocyte infiltration. Necrotizing vasculitis affected the medium-
sized arteries, with fibrinoid necrosis of the vessel walls and intraparietal
and perivascular leukocyte infiltration (Fig. 1C). Immunofluorescent
evaluation showed intense, massive staining (for IgG, IgM, and C3) of the
huge deposits filling the capillary lumen, associated with only faint and
irregular parietal deposits (Fig. 2A). Electron microscopic examination
confirmed the presence of huge intraluminal deposits with a specific
annular and cylindrical structure. Some subendothelial parietal deposits
also were found (Fig. 3A).
Immediate therapy comprised plasma exchange (14 sessions in 5
weeks), 100 mg/day cyclophosphamide for 5 weeks, and 75 mg/day
prednisone for one month, subsequently tapered to 25 mg/day by the end
of one month. After 5 weeks of therapy, the serum creatinine had fallen to
the normal range (1.1 mg/dl), proteinuria was less than 1 g/24 hours, the
cryocrit was 1%, ALT had slightly increased to 91 units, C4 was still very
low, and his symptoms had improved (no edema, purpura, or arthralgias).
At discharge, the patient was taking 25 mg/day of prednisone. One month
later he had another episode of rapid deterioration of renal function, and
systemic signs of the disease reappeared after the prednisone was stopped
abruptly because of the appearance of diabetes. Prednisone was resumed
at 50 mg/day, and another cycle of plasma exchange (6 sessions), and of
cyclophosphamide (100 mg/day for 4 weeks) was commenced. Therapy
again led to return to normal of the serum creatinine and disappearance
of the systemic signs. During this acute episode, the ALT values ranged
between 23 and 55 U/liter despite administration of the cytotoxic drug.
During the following two years, the patient’s renal disease was stable;
the serum creatinine remained in the normal range and proteinuria was
less than 1 g/24 hours. New systemic signs included peripheral neuropathy,
confirmed by electromyography, and some minor episodes of purpura
and/or arthralgia. The cryocrit ranged from 4.5% to 11%; the C4 was
persistently low; and ALT levels rose progressively from 42 to 105 U/liter.
The patient was hospitalized again for followup renal and liver biopsies
(two years after the first set of biopsies). The liver biopsy revealed chronic
active hepatitis of moderate severity. A second percutaneous renal biopsy
specimen, containing 28 glomeruli, showed a mild diffuse and segmental
mesangial proliferation with mild mesangial matrix expansion (Fig. 1D).
The intracapillary monocyte infiltration, huge intraluminal deposits, and
basement membrane double contours seen in the first biopsy had com-
pletely disappeared. In contrast, the interstitial lesions were unchanged,
with a very mild interstitial sclerosis and focal areas of leukocyte infiltra-
tion. The arteries were not affected by necrotizing vasculitis, and the
arterioles showed only mild hyalinosis. Immunofluorescent examination
revealed only few scattered granular parietal deposits of IgG and IgM
without intraluminal staining (Fig. 2B).
Patient 2. A 49-year-old woman was admitted to the S. Carlo Hospital
because of a history of arthralgias over 5 months, edema of the legs,
arterial hypertension, elevated liver enzymes, nephrotic-range proteinuria,
a reduced serum C4 level, and positive serum cryoglobulins. At admission
her serum creatinine concentration was 1.2 mg/dl, and proteinuria ranged
between 1.5 and 3.0 g/day, with reduced total serum proteins (5.7 g/dl).
The cryocrit was 4.5%; characterization of the cryoglobulins revealed a
mixed (IgG-IgMk) cryoglobulinemia, and serum C4 levels were very low.
Hepatomegaly was present and the ALT was 120 U/liter. Markers for
HBV infection were negative, except for HBcAb; at the time, a method for
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Fig. 1. (A) Patient 1, first biopsy. The glomerulus shows a marked endocapillary hypercellularity, mainly a massive infiltration of inflammatory
mononuclear leukocytes (also in 1B). Mesangial cell proliferation and mesangial matrix expansion are mild. The majority of loops show a thickened
glomerular capillary wall, with frequent double-contoured or split basement membrane. Huge deposits (“intraluminal thrombi”), which stain green or
red, fill the capillary lumina (Masson trichrome 3250). (B) Patient 1, first biopsy. Immunohistochemical staining with anti-monocyte-macrophage
antibody (CD68) confirms the massive intracapillary accumulation of these mononuclear leukocytes (immunoperoxidase 3250). (C) Patient 1, first
biopsy. The medium-sized renal artery presents diffuse fibrinoid necrosis of the vessel wall (in red) and intraparietal and perivascular leukocyte
infiltration (Masson trichrome 3250). (D) Patient 1, second biopsy. Glomerulus shows only mild segmental mesangial proliferation and moderate
mesangial expansion. No thickening of the capillary walls, intraluminal deposits or intracapillary leukocyte infiltration are detectable (Masson trichrome
3250). (E) Patient 2, first biopsy. Glomerulus shows global endocapillary hypercellularity (mainly due to infiltration of mononuclear cells) and diffuse
thickening of capillary walls with double-contoured appearance, as in Fig. 1A. On the contrary, there are no intraluminal thrombi (Masson trichrome
3250). (F) Patient 3. A membrano-proliferative pattern, with intense mesangial proliferation and peripheral expansion associated with centrolobular
sclerosis (lobular MPGN) is evident. Moderate endocapillary infiltration of mononuclear leukocytes also is present (Masson trichrome 3250).
diagnosing HCV infection was not available. A liver biopsy showed mild
active chronic hepatitis.
A percutaneous renal biopsy revealed a marked glomerular hypercel-
lularity, mainly an accumulation of monocytes/macrophages (Fig. 1E).
Diffuse thickening of the glomerular basement membrane also was
present, with subendothelial deposits and a double-contour appearance,
but without intraluminal deposits (Fig. 1E). The interstitium and vessels
were normal. Immunofluorescent examination showed diffuse intense
Fig. 1. Continued.
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granular staining for IgM and IgG in the capillary wall subendothelium,
with no intraluminal staining (Fig. 2C). Electron microscopic evaluation
disclosed macrophage interposition in double-contoured capillary walls,
with phagocytic activity (Fig. 3B). Cyclophosphamide (150 mg/day orally)
was administered for 8 weeks; the edema disappeared, proteinuria fell to
only a trace amount, and the serum protein and C4 levels returned to
normal. The ALT values were unchanged.
The patient was followed for the next 21⁄2 years in our clinic. Her general
Fig. 1. Continued.
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Fig. 2. Immunofluorescence micrographs. (A) Patient 1, first biopsy. Intense massive staining of some of the deposits filling the capillary lumina (see
Fig. 1A). Faint and irregular parietal deposits (IgG, 3250). (B) Patient 1, second biopsy. Few scattered segmental parietal deposits (IgG, 3250).
(C) Patient 2, first biopsy. Diffuse granular subendothelial deposits along the capillary walls, without intraluminal staining (IgM, 3250). (D) Patient 3.
Intense diffuse granular staining of peripheral loops (peripheral lobular pattern) (IgM, 3250).
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condition was good, and she had no systemic signs of mixed cryoglobulinemia.
The serum creatinine level was consistently in the normal range. Proteinuria
was absent, and no cryoglobulins were detectable in the serum. The ALT
progressively increased and reached 208 U/liter in the last year. She was
re-admitted to our Unit for followup liver and renal biopsies. The ALT was
113 U/liter, and a liver biopsy now revealed chronic persistent hepatitis. The
urine was normal. A second renal biopsy specimen containing 33 glomeruli
showed mild mesangial proliferation and mesangial matrix expansion; these
Fig. 2. Continued.
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Fig. 3. Electron microscopy. (A) Patient 1, first biopsy. Huge intraluminal deposit totally fills the capillary lumen. Subendothelial parietal deposits are
present. Inset showing a specific annular and cylindrical structure of deposits (original magnification 33,600; inset 322,000; uranyl acetate and lead
citrate. Courtesy of Dr. E. Schiaffino, Pathology Department, S. Carlo Borromeo Hospital, Milan). (B) Patient 2, first biopsy. Double-contoured
basement membrane characterized by interposition of macrophages with intracytoplasmic deposits, expression of their intense phagocytic activity
(original magnification 32800; uranyl acetate and lead citrate. Courtesy of Dr. E. Schiaffino, Pathology Department, S. Carlo Borromeo Hospital,
Milan).
findings were similar to those of the second biopsy of Patient 1 (Fig. 1D).
Immunofluorescent examination revealed granular parietal deposits of IgG
and IgM, which were more segmental and less intense than in the first biopsy.
Six months later, cryoglobulins again were detectable in the serum, and
the C4 was very low. Clinically, the patient was doing well. One year later,
proteinuria (1.1–1.4 g/day) reappeared; the serum creatinine concentra-
tion was normal, and the ALT was 146 U/liter. Prednisone (25 mg/day)
was given for three months, without a reduction of proteinuria. Two years
after the second renal biopsy, the patient was admitted to the hospital
because of a flare of the systemic disease, characterized mainly by
recurrent purpura and abdominal pain. The serum creatinine had rapidly
increased to 2.6 mg/dl, proteinuria was in the nephrotic range, and the
serum total proteins were reduced (4 g/dl). Anti-HCV antibodies (RIBA)
were present in the blood, with positivity for HCV-RNA; genotype
characterization was 1b. The ALT was 377 U/liter. Three intravenous
boluses of 500 mg of methylprednisolone followed by 40 mg of oral
prednisone were given, but the steroid treatment had to be interrupted
after 15 days because of severe hyperglycemia. Interferon-alpha (3 million
units thrice weekly) was started. Within a few days the systemic signs
disappeared, the serum creatinine level returned to the normal range,
proteinuria decreased to 0.4 g/day, the ALT fell to 60 U/liter, and the
HCV RNA became undetectable. Antiviral treatment with interferon-
alpha for 11⁄2 years (reducing the dosage after the end of the first year)
completely controlled all signs of the disease: proteinuria was consistently
below 0.5 g/day, the ALT ranged between 60 U/liter and 85 U/liter, the
serum creatinine level was in the normal range, and the cryocrit was low.
Patient 3. A 56-year-old woman was admitted to our Unit for evaluation
of a proteinuric renal disease, thought to be due to mixed cryoglobuline-
mia. Her medical history was notable for many episodes of recurrent
purpura and arthralgia during the previous 17 years, with the presence of
IgG-IgM cryoglobulins (treated 10 years before in another hospital with
azathioprine and steroids) and the appearance of measurable proteinuria
(1.5 g/day), elevated serum creatinine (1.9 mg/dl), and very high blood
pressure (up to 220/130 mm Hg) for the previous 6 months.
At admission, she had severe arterial hypertension (205/100 mm Hg)
and purpura and edema of the legs. Serum creatinine concentration was
2.0 mg/dl. Proteinuria was 1.9–3.9 g/day; cryocrit was 1.5%, and cryoglobu-
lins were characterized as IgG-IgMk. The ALT was 7 U/liter, and HBV
markers were negative, except for HBsAb. A percutaneous renal biopsy
specimen containing 30 glomeruli showed intense mesangial proliferation
and mesangial matrix expansion and peripheral interposition, with cen-
trolobular sclerosis (lobular MPGN), with some degree of monocyte/
macrophage endocapillary infiltration (Fig. 1F). The interstitium was
normal; mild arteriolar hyalinosis was present. Immunofluorescent exam-
ination showed an intense diffuse granular staining of peripheral loops
(peripheral lobular pattern) for IgG and IgM (Fig. 2D). Treatment with
plasma exchange (10 sessions) and cyclophosphamide (150 mg/day, sub-
sequently reduced to 100 mg/day, for 16 weeks) lowered the serum
creatinine level to normal (1.1 mg/dl) and reduced the proteinuria to
below 0.5 g/day. The ALT remained in the normal range. Stored serum,
collected at the time of biopsy, subsequently revealed the presence of
anti-HCV antibodies.
DISCUSSION
DR. GIUSEPPE D’AMICO (Chief, Division of Nephrology,
San Carlo Hospital, Milano, Italy): I have offered three
patients with cryoglobulinemic glomerulonephritis to illus-
trate the renal involvement in patients with hepatitis C
virus (HCV) infection because it is universally accepted
that this type of glomerular disease, sometimes associated
with renal vasculitis, is the most frequent, if not the sole
renal complication of this viral infection. The renal disease
associated with mixed cryoglobulinemia in patients infected
with HCV, with its several distinctive features, will be the
subject of my Forum.
Definition and classification of mixed cryoglobulinemias
with HCV infection
Mixed cryoglobulins (MCs) are proteins that precipitate
from serum cooled to 4°C, and are composed of a poly-
clonal immunoglobulin G (IgG) bound to another immu-
noglobulin that acts as an anti-IgG rheumatoid factor (RF).
Two types of MCs can be identified, according to the
universally used classification of Brouet et al introduced
some 25 years ago [1]. In type-II MCs, the antiglobulin
component, usually of the IgM class, is monoclonal; in
type-III MCs, it is polyclonal. The majority of MCs, defined
as “secondary mixed cryoglobulins,” have been detected in
patients with connective tissue disorders, lymphoprolifera-
tive disorders, non-infectious hepatobiliary diseases, or
immunologically mediated glomerular diseases. Until the
end of the 1980s, the cause of approximately 30% of both
type-II and type-III mixed cryoglobulinemias was not clear;
this subset of cryoglobulinemias was called “essential” [2].
Over the past 7 years, anti-HCV antibodies and HCV RNA
(a marker of active viremia) have been detected in the great
majority (up to 90%) of patients with “essential” mixed
cryoglobulinemia of both types [3–13]. Positivity for HCV
RNA was even greater in the cryoprecipitate [9, 12, 14, 15].
According to Cacoub et al [10], type-II mixed cryoglob-
ulinemia, especially that with IgMk RF, was significantly
more frequent than was type-III in patients with HCV
infection as compared with those with “essential” mixed
cryoglobulinemia not associated with HCV. In patients
with HCV-associated mixed cryoglobulinemia, there was a
more frequent coexistence of previous hepatitis B infection
(HBcAb). The inverse relationship, that is, the prevalence
of mixed cryoglobulinemia in a large series of patients with
HCV infection and variable concomitant liver involvement,
also has been investigated [16–19]. Lunel et al [16] and
Adinolfi et al [17] found MCs, mainly type III, in 69 of 127
patients (54%) and in 139 of 303 patients (46%) with
HCV-associated chronic liver disease, a prevalence much
higher than that in control patients with HBV-associated
chronic active hepatitis, in whom only 6 of 40 patients
(15%) and 4 of 81 patients (5%) had circulating cryoglobu-
lins. Pawlotsky and colleagues detected MCs in 36% of 59
patients with chronic liver diseases due to HCV infection
[18]. Wong and coworkers, studying 113 consecutive pa-
tients referred because of the presence of anti-HCV anti-
bodies (not necessarily associated with liver involvement),
found MCs in 21 of them (19%): they were of type III in 19
and of type II in only 2 patients [19]. All these studies
suggest that HCV infection is involved in the pathogenesis
of the mixed cryoglobulinemias that formerly have been
termed “essential.”
Renal involvement in type-II mixed cryoglobulinemia:
Cryoglobulinemic glomerulonephritis
Hepatitis C virus infection is associated with both types
of MCs, but more frequently with type-III. Fifteen years
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ago, Cordonnier et al reported, and many subsequent
studies have confirmed, that the well-characterized pattern
of glomerular disease termed “cryoglobulinemic glomeru-
lonephritis” occurs almost exclusively when type-II MCs
are detected in serum, with IgMk RF being the most
frequent monoclonal component [20].
Histologic features of cryoglobulinemic GN. The most
frequent histologic picture found in patients with type-II
mixed cryoglobulinemia and HCV infection is that of
membranoproliferative GN (MPGN) with subendothelial
deposits. However, especially in the more acute stages of
the disease, cryoglobulinemic GN has some distinctive
features that differentiate it from idiopathic type-I MPGN.
As Patients 1 and 2 illustrate (Fig. 1A, 1B, 1E), the
glomerulus is markedly hypercellular because of a massive
infiltration of leukocytes, mainly monocytes [21–24]. Our
group showed that, on average, the number of infiltrating
leukocytes is four times greater in cryoglobulinemic GN
than in severe proliferative lupus nephritis [24]. Further,
these leukocytes express anti-tissue factor procoagulant
activity even more frequently than in lupus nephritis and
are therefore activated cells [24]. Electron microscopic
examination reveals that these leukocytes are in close
contact with the endocapillary and subendothelial deposits
and contain intracytoplasmic deposits (Fig. 3B) [25, 26].
Intraglomerular deposits, commonly found in a suben-
dothelial location, as in all the MPGNs, sometimes also fill
the capillary lumen, especially in patients with an acute,
rapidly progressive deterioration of renal function, for
example, Patient 1 at the time of the first biopsy (Figs. 1A,
2A, 3A). These large eosinophilic, PAS-positive intralumi-
nal deposits, called “intraluminal thrombi,” are usually
amorphous, immune-complex-like deposits. Sometimes,
however, the huge intraluminal deposits and the subendo-
thelial deposits are revealed by electron microscopy to have
a specific fibrillar or cylindrical structure [26–28] that is
identical to that of the in-vitro cryoprecipitate of the same
patients. This structure consists of cylinders that are 100 to
1000 mm long and have a hollow axis, appearing in cross
sections like annular bodies (Fig. 3A). We confirmed that
the subendothelial and intraluminal deposits are identical
to the circulating type-II MCs, even when they have an
amorphous appearance, by demonstrating the same idio-
type of the circulating monoclonal IgM RFs in renal biopsy
specimens [29].
Although thickening of the glomerular basement mem-
brane (GBM), with a double-contoured appearance, is
diffuse and visible in the acute stages of the disease (Figs.
1A, 1E), and even more diffuse and visible than in lupus
nephritis and in idiopathic MPGN, the peripheral interpo-
sition of the mesangial matrix and mesangial cell between
the GBM and the newly formed basement-membrane-like
material (in the areas in which the capillary walls are
double-contoured) usually is less evident than in other
primary and secondary type-I MPGN. Ultrastructural anal-
ysis shows that numerous monocytes are interposed periph-
erally and are in close contact with the subendothelial
deposits (Fig. 3B). This interposition might explain why, at
variance with what occurs in idiopathic MPGN, the double-
contoured appearance in cryoglobulinemic GN can disap-
pear or be less evident in later stages of the renal disease in
the same patients, exemplified by the second biopsies of
Patient 1 (Fig. 1D) and Patient 2. This milder mesangial
involvement also might explain why glomerular segmental
and global sclerosis is less severe than in other types of
idiopathic or secondary MPGN, even many years after the
onset of the renal disease (the average number of obsoles-
cent glomeruli was fewer than 10% at the time of biopsy for
100 patients studied by the 3 groups working in Milan) [30],
and end-stage renal failure due to sclerosing nephritis is
rather uncommon.
As Patient 3 illustrates, these distinctive features can be
absent in some patients with HCV infection and cryoglobu-
linemic MPGN, and the histologic (Fig. 1F) and immuno-
histologic (Fig. 2D) picture at biopsy can be that of a type-I
lobular MPGN with evident centrolobular mesangial scle-
rosis, indistinguishable from that of idiopathic MPGN,
except for the presence of monocyte infiltration. In 1986,
we reported that approximately 10% of our patients with
type-II “essential” mixed cryoglobulinemia showed this
histologic pattern [30]. More recently, the incidence has
increased to 20% of our cryoglobulinemic patients with
HCV infection, especially those biopsied (for example,
Patient 3) because of marked proteinuria associated with
moderately reduced renal function without a rapidly pro-
gressive course. In a few of these patients, signs of systemic
involvement due to mixed cryoglobulinemia (especially
purpura) were not present at the time of biopsy, and only
an intensive search for circulating cryoglobulins made a
correct diagnosis possible.
These various histologic features, all of which can be
generically grouped as MPGN with subendothelial depos-
its, occur in about 80% of patients with HCV-associated,
type-II mixed cryoglobulinemia and glomerular involve-
ment. In the remaining 20%, the biopsy specimen at
presentation (the clinical renal syndrome usually being
characterized by mild urinary abnormalities) or a re-biopsy
after intensive immunosuppressive treatment shows the
histologic pattern of a mild mesangial proliferative GN,
with moderate or no infiltration of leukocytes (as in the
second biopsies of Patient 1 (Fig. 1D) and Patient 2). In
these circumstances, the immunohistologic pattern is also
barely distinctive for cryoglobulinemic GN, because depo-
sition of immunoreactants (usually the ones that compose
the MCs, that is, IgM and IgG) is scanty and segmental, as
in Patient 1 (Fig. 2B). Obviously, when this type of histo-
logic and immunohistologic pattern appears in a patient
with HCV infection, only a complete history and an exhaus-
tive search for type-II MCs can enable one to reach the
diagnosis of cryoglobulinemic GN.
Nephrology Forum: Cryoglobulinemic GN658
Finally, at least one-third of patients with cryoglobuline-
mic GN have acute vasculitis of the small- and medium-
sized renal arteries [31], which is characterized by fibrinoid
necrosis of the arteriolar wall and infiltration of monocytes
in and around the wall (see Fig. 1C). This renal vasculitis,
which is sometimes associated with other signs of systemic
vasculitis (purpura, mesenteric vasculitis presenting as se-
vere abdominal pain), also can appear in the absence of
obvious glomerular involvement. Even when the fibrinoid
necrosis of the renal arterial walls is severe, we have never
found segmental necrosis of the capillary loops with wide-
spread crescentic extracapillary proliferation (now univer-
sally considered the equivalent of vasculitic damage of the
glomerular capillaries) in our large experience [30, 31].
Thus, vasculitic damage likely is limited to larger arterial
vessels.
Clinical manifestations and clinico-pathologic correlations.
In most patients, cryoglobulinemic GN is diagnosed be-
tween the fifth and the sixth decade of life. In the 105
patients whom we studied, the mean age at presentation
was 52.7 6 10.6 years [31]. Women slightly outnumber
men. Signs of mixed cryoglobulinemia frequently become
manifest many years before the renal diagnosis is made, but
renal and extrarenal manifestations appear concurrently in
some patients. In our experience, the median interval
between the first systemic sign of mixed cryoglobulinemia
and renal involvement was 48 months (range, 0 to 492
months); the onset of renal and extrarenal manifestations
was concomitant in 14 of our 105 patients (31). Purpura
(70%) and arthralgias (50%) were the most frequent
extrarenal signs, but neuropathy also was present in 22% of
patients [31].
The most frequent syndrome in cryoglobulinemic GN is
proteinuria with microscopic hematuria, often with evi-
dence of moderate chronic renal insufficiency (55% in our
experience). An acute nephritic syndrome, characterized by
a sudden rise in serum creatinine and severe proteinuria, is
the first renal manifestation in about 25% of patients; this
acute syndrome is complicated by oliguria in approximately
5% of cases. Nephrotic syndrome affects another 20% of
patients [23, 32, 33]. Arterial hypertension is observed in
more than 80% of patients at the time of onset of the renal
disease [23, 31, 32].
The systemic signs of mixed cryoglobulinemia and the
renal signs can vary remarkably. Fluctuation of the extra-
renal symptoms (purpura, other signs of systemic vasculitis,
arthralgias, fever) is the most frequent course; periods of
exacerbation alternate with periods of quiescence. Often
the exacerbation of the extrarenal signs is associated with
an exacerbation of the renal disease (recurrent episodes of
nephritic or nephrotic syndrome), although partial or total
prolonged remission can occur spontaneously or after
treatment in 10% to 15% of patients independently of the
course of the systemic disease, even in patients who at
presentation had acute renal insufficiency or severe ne-
phrotic syndrome (as illustrated by Patient 2). Conversely,
the renal disease can flare in the absence of an extrarenal
exacerbation. In the majority of patients, the renal disease
follows an indolent course and does not progress to end-
stage renal failure despite the persistence of urinary abnor-
malities and even of some degree of renal dysfunction.
Arterial hypertension, which frequently is severe and diffi-
cult to control, predisposes the patient to the cardiovascu-
lar and cerebrovascular accidents often responsible for
death.
Terminal renal failure requiring dialysis is relatively rare,
even many years after the onset of cryoglobulinemic GN. In
the large series of patients with cryoglobulinemic GN
studied in Milan, only 15 of 105 patients required regular
dialysis after a mean followup of 131 months [31]. Of these
105 patients, 42 patients died during the period of followup
because of extrarenal complications; cardiovascular com-
plications (12 patients), infections (9 patients), liver failure
(8 patients), and neoplasias, usually of hematologic origin
(4 patients), were the major causes of death [31]. The
10-year probability of being alive without dialysis for our
population of 105 patients was 49%. Older patients and
patients with recurrent purpura, high serum cryocrit, low
serum C3 levels, and high serum creatinine levels at
presentation were more likely to die or to reach end-stage
renal failure [31].
The clinicopathologic correlations in cryoglobulinemic
GN are illustrated by today’s three case reports. The
nephritic syndrome with rapidly progressive renal insuffi-
ciency usually is associated with the presence of massive
intraluminal thrombi, necrotic vasculitic lesions, or both
(Patient 1 at the first biopsy). The nephrotic syndrome is
associated with exudative MPGN (Patient 2 at the first
biopsy) or lobular MPGN (Patient 3). The histologic pic-
ture of mesangioproliferative GN found at the second
biopsy after intensive treatment in Patients 1 and 2 is
sometimes seen in non-treated patients with mild signs of
renal disease (urinary abnormalities and normal renal
function). Patients 1 and 2 illustrate the effects of immu-
nosuppressive treatment on the clinical course and on the
histologic and immunohistologic features. I do want to
emphasize that in a few patients with a nephritic syndrome
and rapid deterioration of renal function who were referred
to our Unit with a delay of one to two weeks, renal function
and the extent of proteinuria already had improved without
any therapy by the time of admission. These patients
continued to improve despite histologic findings similar to
those in Figure 1A, and in the absence of any therapeutic
intervention. In other words, some acute flares of cryo-
globulinemic GN (probably no more than 5%–10%), espe-
cially those probably due to acute massive intraglomerular
precipitation of cryoglobulins or acute renal vasculitis, can
spontaneously reverse.
Laboratory findings. Circulating serum MCs, specifically
type-II MCs in which the monoclonal rheumatoid factor is
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almost invariably an IgMk, are a distinguishing feature of
cryoglobulinemic GN. Their amount, measured usually as
cryocrit, varies from one patient to another, and in the
same patient at different times (ranging between 2% and
70%). As Patient 2 illustrates, MCs can become tempo-
rarily undetectable during the course of the disease. A weak
correlation exists between the amount of circulating cryo-
globulins and the severity of the extrarenal and renal signs
of the disease.
The serum complement pattern, which does not change
very much with changes in clinical activity, is also distinc-
tive. Serum C4 levels usually are very low, almost undetect-
able, as is the other early component, C1q. Periodically C3
is moderately reduced. This consumption of the early
serum complement components, with the characteristic
sparing of C3, might be attributed to the C4-binding
protein that controls the mechanism of the classic pathway
C3 convertase (34).
Treatment. In the past, acute flares of so-called essential
cryoglobulinemic GN were widely treated with steroids,
plasmapheresis, and frequently cyclophosphamide (as illus-
trated by today’s patients). We have found high-dose
steroids, usually starting with intravenous boluses of meth-
ylprednisolone (0.5–1.0 g/day), useful in patients with loss
of renal function, especially when given in combination
with plasmapheresis, which removes circulating cryoglobu-
lins, thus preventing deposition in the glomeruli and vessel
walls, and cyclophosphamide, which addresses the vascu-
litic injury and inhibits the production of monoclonal
rheumatoid factors by the B-lymphocytes. We also used low
doses of oral steroids to control the systemic signs of mixed
cryoglobulinemia in less acute stages of the renal disease.
We monitored liver enzymes as markers of liver damage,
especially in patients with overt liver disease. With a few
exceptions of reversible, moderately increased ALT levels
(for example, Patient 1), we found no consistent evidence
of acute hepatic damage with the combination of these
drugs in almost 100 treatment courses.
Obviously, the current understanding of the association
between cryoglobulinemic GN and HCV infection has
changed the rationale for the treatment of the systemic
disease and its renal complications, and has prompted the
use of an antiviral drug. Interferon-alpha (IFNa), already
tested in “essential” mixed cryoglobulinemia because of its
potential antiproliferative and immunoregulatory proper-
ties, has had promising results. Although now the most
extensively used antiviral agent for HCV infection, the
efficacy of IFNa in cryoglobulinemic GN is still controver-
sial. The only three controlled trials with this drug were
performed in patients with clinically active mixed cryoglob-
ulinemia associated with HCV infection, but without
clearly established renal involvement [35–37]. In only one
of the trials [36] did 75% of patients have renal involve-
ment, which tended to improve (such as a small reduction
in serum creatinine without a significant change in protein-
uria). Johnson et al performed an uncontrolled study in 14
patients with MPGN associated with HCV infection and
chronic active hepatitis; not all of the 14 had clear evidence
of concomitant mixed cryoglobulinemia. Interferon a re-
duced proteinuria by 60% without significantly changing
serum creatinine levels [38].
A review of the literature on IFNa treatment of patients
with HCV infection (associated or not with mixed cryoglob-
ulinemia and cryoglobulinemic GN) and our own experi-
ence with 28 patients with the renal disease at different
stages, lead me to proffer the following comments:
(1) IFNa is an effective drug for the complications of
HCV infection almost exclusively in patients whose viremia
(as measured by HCV-RNA levels) clears, a response that
is mainly related to the specific genotype (1b being less
responsive than others) and to the magnitude of the initial
viremia.
(2) The favorable effect usually lasts for only a short
period after treatment is discontinued and generally is
followed by a virologic rebound and a clinical flare within a
few months.
(3) The renal manifestations seem to respond less satis-
factorily than does the extrarenal involvement, including
the liver disease and cryocrit.
(4) In patients with cryoglobulinemic GN and systemic
manifestations of mixed cryoglobulinemia, IFNa is fre-
quently administered in combination with variable doses of
steroids, which seem to potentiate the beneficial effects of
the antiviral agent. These include a faster and longer-
lasting remission of the systemic manifestations of mixed
cryoglobulinemia (as in Patient 2).
(5) In the presence of acute cryoglobulinemic GN (an
acute nephritic syndrome with rapidly developing renal
insufficiency or a nephrotic syndrome with slower deterio-
ration of renal function, usually associated with the recur-
rence of the systemic signs of mixed cryoglobulinemia,
especially systemic vasculitis), IFNa does not prevent pro-
gression of renal damage. Combination therapy with anti-
inflammatory and cytotoxic drugs, and sometimes also
plasma exchange, is still necessary.
Our current policy is to combine IFNa (3 million units 3
times/week for 6 to 12 months) with high doses of oral
steroids, rapidly tapered to low maintenance doses admin-
istered for many months. In more severe cases, especially if
massive glomerular precipitation of cryoglobulins and/or
presence of renal vasculitis is suspected or documented by
biopsy, steroid treatment is started with three intravenous
high-dose boluses (0.75–1.0 g/day of methylprednisolone
for 3 consecutive days); plasmapheresis (exchanges of 3
liters of plasma 3 times/week for 2 or 3 weeks) and/or
cyclophosphamide (2 mg/kg body weight for 2 to 4 months)
are added.
We are coordinating in Italy a multicenter controlled
trial comparing steroids plus cyclophosphamide given alone
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or followed by IFNa during acute flares of cryoglobuline-
mic GN to evaluate the possible adverse effects of the
anti-inflammatory and immunosuppressive therapy when
given alone on the course of the viral disease and its organ
complications (an increase in the level of hepatitis C
viremia during treatment with corticosteroids or cyclophos-
phamide has been described [39, 40]). We also hope to
determine whether IFNa can protect against the viral
disease.
Pathogenesis of HCV-associated GN
Evidence has been accumulating in recent years that
hepatitis C virus directly infects circulating peripheral
blood mononuclear cells [41–44] and bone marrow cells
[44–46] in most patients with type-III and type-II mixed
cryoglobulinemia, and even in some patients without con-
comitant cryoglobulinemia [41, 42]. It has been hypothe-
sized that HCV infecting the B-lymphocytes stimulates
them to synthesize the cryoprecipitating polyclonal RFs
responsible for type-III mixed cryoglobulinemia. In some of
the patients with polyclonal B-cell activation, additional
but-as-yet uncharacterized events (such as duration of the
HCV infection or superimposed infection with other vi-
ruses, such as HBV or EBV) might induce a shift to the
abnormal proliferation of a clone of B cells producing a
monoclonal IgM RF, thus inducing a type-II mixed cryo-
globulinemia. Agnello showed that these monoclonal RFs
bear the WA cross-idiotype and postulated that type-II
MCs result from chronic stimulation of a population of XId
WA1 B-1a cells by HCV-lipoprotein [47, 48]. We demon-
strated that peripheral B-lymphocytes of cryoglobulinemic
patients produce increased amounts of IgM RF in vitro,
both spontaneously and after stimulation with pokeweed
mitogen [49]. Moreover, clonal expansion of IgM-produc-
ing cells has been reported recently [46, 50–53], and its
reversibility after IFNa therapy in some patients also has
been documented [53]. This hypothesis, which considers
mixed cryoglobulinemia a benign lymphoproliferative dis-
order, might explain why overt B-cell malignancy occurs in
some of these patients [31, 46, 52, 54, 55]. We have
documented non-Hodgkin’s lymphoma in 4 of our 65
patients who have had type-II mixed cryoglobulinemia with
cryoglobulinemic GN for many years (unpublished data).
We have induced in mice an MPGN very similar to
human cryoglobulinemic GN by intravenously injecting
solubilized type-II MCs from patients with this renal dis-
ease and HCV infection [56]. The monoclonal IgMk RF
isolated from such MCs, which certainly contained no viral
antigenic component, when injected separately deposited
in the glomerulus. This RF deposition suggested a specific
affinity of IgM RF component of the cryoglobulins for a
particular glomerular structure. Such an affinity already has
been demonstrated by Solomon for light chains in light-
chain nephropathy [57]. Recently we demonstrated that the
same purified IgMk binds to cellular fibronectin, a known
constituent of mesangial matrix [58]. This property was not
displayed, however, by purified monoclonal IgM from
patients with Waldenstro¨m’s disease, polyclonal IgM from
patients with rheumatoid arthritis, or polyclonal IgM from
normal subjects [58].
Our current view about the pathogenesis of the glomer-
ular disease associated with HCV infection is illustrated in
Fig. 4. Proposed pathogenetic mechanisms for
HCV-associated glomerulonephritis (modified
from Ref. 59). IC, immune complex.
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Fig. 4 [59]. We think that the prevalent pathogenetic
mechanism is deposition in the glomerulus of a monoclonal
IgM RF with particular affinity for the glomerular matrix,
an RF produced by permanent clones of B lymphocytes
infected by the virus. We do not know yet whether the IgM
RF deposits in the glomerulus: (1) alone, with subsequent
in-situ binding of IgG (perhaps bound already to viral
antigens); (2) as a mixed IgG-IgM cryoglobulin, not bound
to HCV antigens or; (3) as a complex composed of HCV
antigens, IgG anti-HCV antibodies, and IgMk RF. Dem-
onstration of HCV RNA or virus antigens in the glomeruli
has remained elusive [8, 9, 12], and only recently have
specific HCV-related proteins been detected in glomerular
and tubulo-interstitial vascular structures by indirect immu-
nohistochemistry, using electroelution of tissue sections to
enhance the sensitivity of the method [60]. However, the
evidence that immune complexes containing intact virion
are the main component of the glomerular deposits is
scanty, while complexes containing HCV capsular antigens
cannot be excluded. As depicted in the left section of the
figure, it is possible that in a minority of cases immune
complexes composed of HCV antigens and anti-HCV IgG
antibodies deposit directly in the glomerular structures, in
the absence of a concomitant type-II MC with a monoclo-
nal IgM RF, inducing an immune complex GN similar to
that described in patients infected with hepatitis B virus
[61]. Such a mechanism could explain the non-cryoglobu-
linemic GN described by Johnson in patients with HCV
infection [38].
Is cryoglobulinemic GN always due to HCV infection? Is
glomerulonephritis associated with type-II mixed cryoglobu-
linemia the only glomerular disease induced by HCV infec-
tion? A repeated search for the markers of HCV infection
was negative in 15% of our patients with cryoglobulinemic
GN. Another agent must be the stimulus for the production
of monoclonal IgMk RF in these patients. The prevalence
of cases of cryoglobulinemic GN apparently not due to
HCV infection seems to be even higher in northern Europe
than in Italy (personal observation). It is worth emphasiz-
ing that in our experience, the renal disease in non-HCV
cryoglobulinemic GN is clinically and histologically indis-
tinguishable from that associated with HCV infection.
The answer to the second question is more controversial.
In the USA, Johnson reported 34 patients with proteinuria,
circulating anti-HCV antibodies, and a histologic picture of
membranoproliferative or proliferative-exudative GN [38].
Of these 34, 14 did not show positivity for MCs at presen-
tation. Although circulating cryoglobulins were found in 9
of them subsequently, the 5 remaining patients apparently
had a non-cryoglobulinemic glomerulonephritis [38]. Also,
Japanese investigators reported the absence of MC but the
presence of HCV antibodies and RNA in 6 of 10 consec-
utive patients with MPGN, only one of whom showed
evidence of cryoglobulinemia [62]. But their subsequent
publication reported positivity for circulating cryoglobulins
in all 6 HCV-positive patients [63]. Isolated cases of
membranous GN in patients with concomitant HCV infec-
tion also have been reported [reviewed in Ref. 64], but the
relationship between the viral infection and the glomerular
disease is hypothetical. The experience in the Mediterra-
nean area of southern Europe, Turkey, and Hong Kong,
where the prevalence of HCV infection is relatively high,
does not support the hypothesis that a glomerular disease
complicates this viral infection, even in the absence of
concomitant type-II mixed cryoglobulinemia. An ongoing
survey among the renal units in Italy has revealed that only
3 of 128 adult patients with biopsy-proven “idiopathic”
type-I MPGN, but without signs of a concomitant mixed
cryoglobulinemia, had HCV infection [59]. In France, the
prevalence of HCV antibodies was nil in 110 adult patients
with primary glomerular disease [65] and in 35 patients with
idiopathic type-I MPGN [66]. In Spain, only one patient
with IgA nephropathy of 70 adult patients with biopsy-
proven chronic primary glomerular diseases had HCV
antibodies [67]. In Turkey, the prevalence of HCV infec-
tion in 52 patients with idiopathic MPGN was similar to
that found in blood donors of the same area [68]. In Hong
Kong, a low prevalence of HCV infection was found in 30
patients with primary membranous and membranoprolif-
erative GN [69]. Finally, Cosio recently reported that the
prevalence of HCV positivity in 105 patients with idiopathic
glomerulopathies from the USA was not significantly
higher compared with a control group with diabetic ne-
phropathy, except in a few cases of focal glomerulosclerosis
in intravenous drug users [70].
Summary
Cryoglobulinemic glomerulonephritis, the most frequent
renal complication of HCV infection, is associated with
type-II mixed cryoglobulinemia, IgMk being usually the
monoclonal rheumatoid factor. This membranoprolifera-
tive GN, which shows some distinctive histologic features
(intraglomerular monocyte infiltration, intraluminal thrombi
due to massive precipitation of cryoglobulins, renal vascu-
litis), has a chronic clinical course with recurrent acute
episodes that can be controlled by corticosteroids and
cyclophosphamide more than by antiviral therapy (interfer-
on-alpha). The affinity of the circulating IgMk RF for the
mesangium appears to be the major factor responsible for
the precipitation of type-II mixed cryoglobulins in the
glomerular structures and the ensuing damage.
QUESTIONS AND ANSWERS
DR. NICOLAOS E. MADIAS (Chief, Division of Nephrology,
New England Medical Center, Boston, Massachusetts, USA):
Thank you very much, Dr. D’Amico, for a wonderful
discussion. What is our best understanding of why only a
certain fraction of HCV patients develop cryoglobulinemic
GN? For example, do the duration of the disease, the viral
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load, the viral genotype, or the number of mutations
matter?
DR. D’AMICO: That is a very good question, to which
there is no definitive answer at present. We did not find any
evidence for a role of the genotype of the virus, as our
patients with HCV infection and cryoglobulinemic GN had
the same relative prevalence of the different genotypic
subgroups as did our population of cryoglobulinemic pa-
tients without evidence of renal involvement [71]. Accord-
ing to the pathogenetic hypothesis that I have proposed, in
some patients with circulating type-III cryoglobulinemia,
unknown mechanisms induce the emergence of a perma-
nent clone of B cells, which produce monoclonal IgMk
type-II cryoglobulinemia. The resultant shift from hyper-
stimulation of RF-producing B cells to the development of
a benign lymphoproliferative disorder must be of para-
mount importance in favoring the occurrence of the renal
complication. I alluded to two potential mechanisms for
this shift: the duration of the viral infection, and therefore
of the B-lymphocyte involvement by the virus; and the
concomitant infection by other viruses. As I mentioned,
observations in support of the first contention have been
published by Cacoub et al [10]. In accord with these
observations, the prevalence of positivity of anti-HBV
antibodies in our population of patients with HCV infec-
tion and type-II MC was significantly higher than that in the
general Italian population (unpublished data). In addition,
we have described a concomitant Epstein-Barr viral infec-
tion in some of our patients with type-II MC and renal
involvement, but not in patients with type-II MC and the
absence of renal damage [72]. Another phenomenon that
we cannot explain is the abrupt, massive precipitation of
cryoglobulins, which takes place occasionally in our pa-
tients with cryoglobulinemic GN, and which gives rise to an
acute aggravation of the renal disease. Such an acute
massive precipitation can occur even with low cryocrits, as
Patient 1 demonstrates. Thus it is likely the quality, more
than the quantity, of the circulating cryoglobulin that is
important.
DR. MADIAS: You alluded to evidence that different
monoclonal light chains have a particular nephrotoxic
potential giving rise to cast nephropathy, light-chain depo-
sition disease, amyloidosis, or no disease at all [57]. Is there
similar evidence that the various morphologic lesions you
described in cryoglobulinemic GN might relate to certain
characteristics of the monoclonal cryoglobulins involved?
DR. D’AMICO: I will ask Dr. Fornasieri to address this
question.
DR. ALESSANDRO FORNASIERI: (Division of Nephrology,
San Carlo Borromeo Hospital, Milano): We studied whether
some physicochemical or serologic properties of cryoglob-
ulin components could explain their different nephrito-
genic potential in mice [56]. The isoelectric point of the
IgMks was anionic in all cases, with a single peak at high
performance chromatofocusing between pH 4.5 to 5.5, thus
excluding any role of electric charge in local binding.
Moreover, the IgG subclasses in our cryoglobulins were
normally represented, and we could not find any IgG3
enrichment, a condition that has been invoked for the
mechanism of cryoprecipitation. We also studied whether
different expression of Vh variable region subgroup on
heavy chains of our cryoglobulins IgM components corre-
lated with their nephritogenicity, using Cc1 and Lc1 anti-
idiotype antibodies that recognize Vh1 and Vh4 variable
region subgroups, but we could not demonstrate any asso-
ciation between these idiotypes and nephritogenicity. Fur-
ther, the amount and composition of IgMk-IgG immunocom-
plexes at 37°C did not explain the different nephritogenicity.
DR. CLODOVEO FERRI: (Department of Medicine and Clin-
ical Immunology, University of Pisa, Pisa, Italy): A number
of clinical and epidemiologic observations suggest that it is
more useful to view mixed cryoglobulinemia as part of the
multi-faceted disorder that is chronic HCV infection. Other
unknown infectious, environmental, and genetic factors
most likely contribute to the appearance of different clini-
cal patterns. The infection of lymphocytes by HCV is
probably decisive for the pathogenesis of various autoim-
mune and lymphoproliferative disorders that can compli-
cate chronic HCV infection. Among these complications
are hepatitis, glomerulonephritis, lung fibrosis, peripheral
neuropathy and systemic vasculitis; lymphomas might com-
plicate mixed cryoglobulinemia or can appear as an isolated
manifestation of HCV infection. All these HCV-related
disorders, including glomerulonephritis, can appear as iso-
lated symptoms or variably combined with other manifes-
tations in the syndrome of mixed cryoglobulinemia.
DR. D’AMICO: I agree with you that we are dealing with
a multi-faceted systemic disorder and that the renal com-
plication is only one aspect of it. What is worth emphasiz-
ing, however, is that type-III cryoglobulinemia is sufficient
to generate the majority of the complications of HCV
infection associated with mixed cryoglobulinemia. Notwith-
standing, a shift to type-II cryoglobulinemia, an entity that
closely simulates a lymphoproliferative disorder, is neces-
sary for developing glomerulonephritis. That might explain
the large number of cases of non-Hodgkin’s lymphoma that
nephrologists find in their HCV patients with MC, probably
higher than rheumatologists find in the general population
of patients with mixed cryoglobulinemia.
DR. MADIAS: How long are patients to be treated in your
trial, especially in view of evidence that a longer course of
treatment–for example 18 months–improves the outcome
of patients with liver involvement?
DR. D’AMICO: Both arms of our randomized trial will be
treated with steroids and cyclophosphamide. One of the
randomized arms also will receive IFNa starting with the
13th week, utilizing a daily dose of 3 million units for the
first 3 months, then shifting to 3 million units 3 times per
week for the next 9 months.
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DR. MADIAS: Do you require that patients be IFNa-naı¨ve
prior to enrollment?
DR. D’AMICO: With the exception of small doses of
steroids, patients must not have been treated for at least 6
months.
DR. DOMENICO SANSONNO: (Department of Medicine, Uni-
versity of Bari, Bari, Italy): The fact that infection with HCV
leads to immune-complex glomerulonephritis in only some
patients with chronic viremia raises important questions
regarding the direct pathogenetic potential of HCV and
points to a potential role of the cryoprecipitating immune
complexes in the induction of glomerular damage. Recently
our group has shown that production of RF activity in
chronically infected HCV patients with type-II mixed cryo-
globulinemia is the result of V-D-J immunoglobulin gene
mutations, suggesting that RF activity is clonally related
and derived from somatically mutated molecules [73].
These findings indicate that the possible gene repertoire for
encoding RF in HCV-infected patients includes multiple
genes and gene combinations not restricted to genes used
in the fetal antibody repertoire. Consequently, there may
be marked heterogenicity in heavy chain production by
individual patients, and combinations of V-D-J immuno-
globulin genes might result in production of RF molecules
with different nephrotoxic potential. My question is: can
molecular differences of RF molecules mediate different
immunopathologic manifestations of chronically infected
HCV patients with type-II mixed cryoglobulinemia?
DR. D’AMICO: As Dr. Fornasieri mentioned earlier, so far
we have not been able to account for the variable nephri-
togenicity of mixed cryoglobulins. In view of the intriguing
findings of your group, the molecular characteristics of the
RF activity of these patients must be investigated.
DR. STEFANO BOMBARDIERI: (Head, Section of Clinical
Immunology, Department of Medicine, University of Pisa): I
would like to add a comment on the pathogenesis of renal
involvement in mixed cryoglobulinemia. As you pointed
out, the renal involvement in this disease is characterized
by spontaneous exacerbations and long-lasting remissions
usually not mirrored by quantitative serologic changes
(cryocrit, serum complement fractions). It appears that the
nephrotoxicity of the complexes could be better explained
by qualitative rather than quantitative changes. I would like
to suggest that changes in the antigen-antibody ratio of the
complexes [74] and appearance of novel nephrotoxic anti-
bodies could explain rapid exacerbations of the disease.
Beyond the monoclonal IgMk RF, we have described a
renal-specific IgG antibody in cryoglobulinemic patients
that is directed toward a 50 Kd renal protein [75].
DR. D’AMICO: I agree with your initial comment. As for
the importance and specificity of these anti-kidney auto-
antibodies, I have some doubt. You probably know that
these auto-antibodies were first demonstrated some years
ago by a group in Manchester in patients with IgA nephrop-
athy [76]. We have confirmed that such auto-antibodies can
be found in many different types of glomerular disease; that
the 50 Kd antigen is of mesangial origin; and that these
anti-mesangial antibodies are a consequence, rather than
the cause, of any mesangial damage, and are capable of
inducing further damage once mesangial antigens have
been unmasked as a consequence of the initial injury [77].
Indeed, our finding these auto-antibodies even in a small
number of normal individuals suggests that these auto-
antibodies can be present in the absence of overt glomer-
ular damage.
DR. FULVIO INVERNIZZI: (Director, Institute of Biomedical
Sciences, University of Milano and S. Paolo Hospital, Mila-
no): My comment relates to the Brouet classification of
cryoglobulins [1]. Recently, a new method of analysis,
two-dimensional polyacrylamide gel electrophoresis, elab-
orated by Dr. Tissot in Lausanne, has provided more
precise information on the isotype and the clonality of an
immunoglobulin that precipitates at a low temperature
[78]. Two new types of cryoprecipitate have been identified:
type II-III, with monoclonal and polyclonal IgM and poly-
clonal IgG; and type II-III variant, representing a mixture
of oligoclonal IgM with trace amounts of immunoglobulins
of different isotypes. Dr. Tissot has studied 62 cryoprecipi-
tates from our patients with cryoglobulinemic syndrome.
The preliminary results show that some clinical correlations
already suggested became more evident. Patients with the
cryoglobulinemic syndrome with type-II cryoglobulins had
higher levels of cryocrit and creatinine, lower C4, and more
severe purpura. On the other hand, liver involvement was
higher when the cryoprecipitate was of type II-III, II-III
variant, or type III. In addition, in a previous study we
found that only patients with type-II cryoglobulinemia (7 of
75) developed lymphoproliferative disease [79]. These re-
sults stress the importance of the immunochemical charac-
terization of cryoglobulins with sensitive methods.
DR. D’AMICO: The observation that different variants of
type-II and -III MC exist is interesting, and the classifica-
tion based on new technologies could help elucidate patho-
genetic mechanisms. While the presence of a variant with
monoclonal and polyclonal IgM, both bound to polyclonal
IgG, is difficult to ascertain because of the possibility of
contamination by polyclonal IgM from serum, the presence
of oligoclonal IgM mounting k light chain has been found
in about 9% of type-II MCs in a study performed by Dr.
Fornasieri in collaboration with Dr. Denis Carson and Dr.
Gregg Silverman in La Jolla (unpublished data). They used
monoclonal antibodies against synthetic peptides corre-
sponding to the products of Vh genes (Vh1, Vh3, Vh4). In
3 of 35 IgMk from type-II MCs, they found antibody
reactivity against more than one product of Vh genes.
DR. GIUSEPPE MONTI: (Head, Department of Medicine,
Hospital of Saronno, Saronno, Italy): The treatment of the
cryoglobulinemic syndrome is still debated and must be
adapted to the clinical course. However, I believe that
IFNa has modified in some cases the natural history of
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mixed cryoglobulinemia associated with the HCV infection.
In fact, according to our own data and those of the Italian
Group for the Study of Cryoglobulinemias (GISC) [80], the
disappearance of HCV-RNA from the serum during ther-
apy coincides with the disappearance of symptoms and of
cryoglobulins, and with improvement of ALT values, pe-
ripheral neuropathy, and liver histology. Thus, long-lasting
favorable effects, when they occur, are observed both in
cryoglobulinemic patients and patients with HCV-related
liver disease without cryoglobulinemia, especially in cases
related to genotype 2A. We are uncertain whether major
renal involvement is less responsive to IFNa than are
extrarenal signs (including liver damage, neuropathy, pur-
pura, and cryocrit) because our clinical experience does not
include many patients with advanced renal disease. We
have never used IFNa in combination with high or low
doses of steroids, and Dammacco et al did not show a
different response to IFNa alone versus IFNa plus steroids
[37].
DR. D’AMICO: I’m convinced that IFNa is of value in
treating cryoglobulinemic GN, and I believe that such
treatment changes the natural history of the disease. We no
longer see the severe flares of the renal disease that we saw
some 10 years ago. Antiviral treatment given before the
patient sees the nephrologist probably has modified the
severity and possibly even the incidence of the renal
complication. On the other hand, nephrologists agree that
after renal damage has occurred and an acute renal flare is
present, therapy with IFNa is not sufficient. Accordingly,
we organized a trial in which all such patients will receive
the immunosuppressive regimen, that is, steroids and cy-
clophosphamide, because we believe this treatment is nec-
essary. However, even without immunosuppressive treat-
ment, IFNa can favorably influence the course of the
glomerular disease, but only in a minority of cases. Patient
2 of today’s protocol is a case in point. Notably, the viral
genotype of that case was 1b, indicating that even with this
genotype, antiviral treatment occasionally can be of value.
I am convinced, however, that for exacerbations of cryo-
globulinemic GN, especially if vasculitic signs are present
or the patient has acute renal failure, we must add some
other remedy to IFNa. We consider cyclophosphamide the
drug of choice for these situations. I must say that although
we consider antiviral therapy essential for these patients,
the type of drug and its dosage is still matter of debate. Dr.
Misiani, who is in the audience, has extensive experience on
this topic and might wish to comment.
DR. ROCCO MISIANI: (Division of Nephrology, Ospedali
Riuniti di Bergamo, Bergamo, Italy): In our experience,
treatment with standard doses of IFNa was initially effec-
tive in many cryoglobulinemic patients whether or not they
had renal involvement. Unfortunately, a relapse of the
disease invariably occurred in the post-treatment period.
Moreover, it is well known that INFa therapy can, in rare
instances, worsen the patient’s condition. This problem is
of particular concern in the presence of cryoglobulinemic
neuropathy or glomerulonephritis. We have observed that
such a deterioration usually occurs in patients who fail to
obtain a virologic response, as measured by the disappear-
ance of HCV RNA from the serum. A possible explanation
is that the immunostimulating effect of INFa becomes
predominant in the absence of antiviral activity. Our recent
experience with higher doses of IFNa is more encouraging.
Using 6 million units thrice weekly for 6 months followed
by 3 million units thrice weekly for 12 months, we obtained
a long-term response in 20% of patients, that is, complete
remission of the clinical syndrome, as well as normalization
of virologic and immunologic tests for at least one year
after cessation of treatment. Even more promising appear
to be our preliminary results with a combination of IFNa
and ribavirin. Patients who proved resistant to IFNa alone
responded to this combination.
DR. MADIAS: Thank you, Dr. Misiani. When you men-
tioned your experience with worsening of renal function
during IFNa treatment, did you imply worsening of the
underlying cryoglobulinemic disease or appearance of
other diseases related to INFa therapy, such as an intersti-
tial nephritis? Also, do you have any experience with IFNb
treatment?
DR. MISIANI: Although different forms of renal damage
appearing during IFNa therapy have been described in the
literature, the deterioration of renal function we have seen
in cryoglobulinemic patients with glomerulonephritis is
usually associated with worsening of immunologic data,
such as serum concentration of cryoglobulins, RF activity,
and C4. This observation suggests an activation of the
underlying cryoglobulinemic disease. With regard to your
second question, we have limited and disappointing expe-
rience with IFNb. All 4 cryoglobulinemic patients we
treated with this drug did not respond, although 2 of them
had an initially favorable response to subsequent treatment
with IFNa.
DR. ANGELO MONTEVERDE (Head, Department of Medi-
cine, Hospital of Novara, Novara, Italy): In D’Amico’s series,
about 15% of type-II mixed cryoglobulinemia cases are
HCV negative, and similar figures are reported by Ameri-
can and British authors. By contrast, in most Italian studies,
fewer than 5% of type-II mixed cryoglobulinemia cases are
HCV negative. In our series of 130 patients with type-II
mixed cryoglobulinemia (observed consecutively over a
10-year period), all tested HCV positive (anti-HCV testing
and/or HCV-RNA determination in serum or peripheral
mononuclear cells) [80]. Thus, from our experience, the
very existence of HCV-negative type-II mixed cryoglobu-
linemia should be questioned. In such a context, the
constant association with chronic HCV infection, the well-
defined clinical manifestations (particularly the vasculitic
phenomena and renal involvement), and the almost con-
stant finding of B-cell lymphoproliferation in the bone
marrow and/or liver identify a distinct disease that can no
Nephrology Forum: Cryoglobulinemic GN 665
longer be defined as “essential” mixed cryoglobulinemia.
This conclusion contrasts with the findings of D’Amico,
suggesting that a significant number of “essential” mixed
cryoglobulinemia cases actually exist. Could these cases be
proven HCV positive at further virologic testing? Have the
virologic tests been repeated at followup?
DR. D’AMICO: We were surprised, quite surprised, when
we found some cases of cryoglobulinemic glomerulonephri-
tis that were negative for the markers of HCV despite
careful testing. Initially, we thought that the negative tests
simply reflected a particular stage of the disease or some
methodologic deficiency. But such was not the case. We
now have been following 5 cryoglobulinemic patients for
many years in whom repeated measurements of anti-HCV
antibodies and HCV-RNA have proven negative. One of
them has a constant positivity for the HBV antigens. Thus
we were forced to modify our initial belief and accept the
idea that a few cases of “essential” mixed cryoglobulinemia
do indeed exist. It is worth emphasizing that the clinical
and/or histologic features of the renal disease in these 5
patients without HCV infection did not differ from those in
HCV-associated cryoglobulinemic GN.
DR. GIAMPAOLO MERLINI (Department of Internal Medi-
cine and Clinical Oncology, University of Pavia, Pavia, Italy):
I would like to comment regarding the second patient
presented today. In this patient, the flare of the systemic
disease was associated with the HCV viremia. It would be
interesting to explore in prospective studies the correlation
between aggravation of systemic manifestations of cryo-
globulinemia and burst of HCV viremia. We are now
beginning such a study at our Institution.
DR. D’AMICO: Thank you for your observations. Pres-
ently, I cannot comment on whether such a correlation
exists, because in our Unit we are not using quantitive
measurements of HCV RNA. These data will be available
at the completion of our multicenter trial.
DR. MADIAS: You indicated that in the large series of
patients with cryoglobulinemic GN from the three nephro-
logical units in Milano, there was a low incidence of ESRD,
on the order of 14% over about 10 years of observation. On
the other hand, about 40% of patients died over this period
of cardiovascular complications, sepsis, liver failure, and
neoplasias [31]. Thus, one might postulate that the low
incidence of ESRD reflects, at least in part, the fact that
patients with severe disease die earlier from nonrenal
causes, including complications of treatment. Also, you
mentioned that at times spontaneous remissions of even
aggressive presentations of cryoglobulinemic GN occur.
Indeed, several clinicians, myself included, share the view
that the relationship between immunosuppressive therapy
and clinical course is not clear-cut in this syndrome. Thus,
excluding enrollment into a controlled trial, what is your
recommendation regarding prudent management of this
entity?
DR. D’AMICO: In Italy, I advise general practitioners to
send these patients to the nephrologist. Since in the US you
have two types of nephrologists, the so-called “private
nephrologist” and the “academic nephrologist,” I would
recommend that private nephrologists send their more
severe cases to academic nephrologists for study and care.
Of course, the specialist must be familiar with the use of
cyclophosphamide and high-dose steroids. I suspect that
intravenous boluses of steroids are not used as frequently in
the US as they are in Italy, where they are one of the most
frequently used treatments in the acute flare of the majority
of glomerulonephritides. We have learned how to use them
without particularly severe toxic effects. Obviously, using
the combination of high-dose steroids plus cyclophospha-
mide substantially increases the risk of complicating infec-
tions, and all of us have witnessed severe septic complica-
tions. However, we cannot disregard the fact that these
aggressive immunosuppressive treatments are carried out
in patients who almost invariably would progress to end-
stage renal failure if treatment were withheld. That is what
happened regularly 30 or even 20 years ago, before we
started to use intravenous boluses of steroids plus cyclo-
phosphamide. With these drugs, it is my distinct impres-
sion—and I think the majority of nephrologists present will
agree with me—that we have modified the natural history
of cryoglobulinemic glomerulonephritis. Now that the viral
pathogenesis has become evident, we are scared of the
possible toxic effect of these treatments on the liver. One of
the aims of our ongoing trial is to find out whether
treatment aggravates the liver disease, especially in the
subgroup of patients treated only with immunosuppressive
therapy.
DR. VITTORIO ANDREUCCI (Director, Institute of Nephrol-
ogy, University of Naples, Naples, Italy): Why was plasma
exchange not used in the second patient presented, even
when, in the second phase of illness, symptoms and ne-
phrotic-range proteinuria reappeared, and serum creati-
nine increased to 2.5 mg/dl? Of course, plasma exchange is
a quite expensive treatment and we have to take into
consideration the cost-benefit ratio. When do you use it?
DR. D’AMICO: The approach of the various nephrological
units in Italy is quite different regarding plasma exchange.
We use it rather frequently, in association with other
immunosuppressive treatments, in the more severe cases.
But I know that some investigators and some groups—and
certainly the group in Pisa has the largest experience—are
using plasma exchange alone. They were using it even
before antiviral agents became available. In their opinion,
plasma exchange can be used without the concomitant
administration of immunosuppressive drugs, which are
supposed to block the rebound production of cryoglobulin
when the level of circulating cryoglobulin is abruptly re-
duced. Now we know that IFNa, given together with
plasma exchange, might reduce this risk of rebound. None-
theless, we do not use plasma exchange without concomi-
tant immunosuppressive treatment. Dr. Moriconi might
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wish to comment about the experience of the Pisa group on
plasma exchange as the sole therapy in cryoglobulinemic
GN.
DR. LUIGI MORICONI (Division of Nephrology, S. Chiara
Hospital, Pisa): We have been using plasma exchange since
1978 in patients with severe cryoglobulinemic GN, in
combination with medium-low doses of corticosteroids,
without the addition of immunosuppressive drugs. We used
to perform prolonged plasma exchange sessions, lasting
several months, to reduce the risk of rebound phenomena.
It is likely that the favorable results obtained reflected
more modifications of the nature of immune complexes
rather than simple removal of cryoglobulins. At present, we
treat patients with acute disease by a semiselective
apheretic technique, double-filtration plasmapheresis
(DFPP), which is very effective in removing cryoglobulins
and modifying the immune-complex quality [74] while
allowing recovery of most of the serum albumin. We now
perform shorter cycles of DFPP (or plasma exchange) than
in the past and add high-dose corticosteroids and/or other
immunosuppressive drugs when the frequency of the
apheretic sessions is reduced or discontinued. Our uncon-
trolled observations suggest that in this way we reduce the
total amount of the drugs administered, while inducing
satisfactory remission of cryoglobulinemic GN.
DR. GIULIO CINOTTI (Director, Institute of Nephrology,
University of Rome, Rome, Italy): Did you mean that in
contrast to HBV infection, which can give rise directly to an
immune-complex glomerulonephritis, the HCV-associated
glomerular disease always arises as a consequence of the
abnormal proliferation of a clone of B-lymphocytes that
produces a monoclonal IgM rheumatoid factor?
DR. D’AMICO: I do not exclude the possibility that HCV
infection can generate an immune-complex-mediated GN
through a mechanism similar to that operative in HBV-
associated glomerular complications. However, in my opin-
ion, the renal complication of HCV infection usually is
mediated through the precipitation of type-II mixed cryo-
globulins in the glomerulus.
DR. CINOTTI: What is the evidence for such a direct effect
of HCV or its cooperation with other hepatotropic viruses?
DR. D’AMICO: In my opinion, the relationship between
hepatotropism and lymphotropism of HCV virus is still to
be studied. The presence of the virus does not necessarily
mean contemporaneous damage of lymphocytes and liver.
It is likely that in some cases the liver is preferentially
involved, immune-complex formation being a consequence
of the liver damage that modifies the immune response. But
in other cases, lymphocytes are also infected. Indeed,
studies by many Italian rheumatologists and immunolo-
gists, several of whom are present here today, have proved
that such an infection of B-lymphocytes is a common
phenomenon, and that it is responsible for the mixed
cryoglobulinemias that complicate about 50% of patients
with HCV-associated liver disease.
DR. FRANCESCO PAOLO SCHENA (Director, Institute of
Nephrology, University of Bari): You stated that there is no
correlation between the level of the cryocrit and the extent
of renal or liver lesions. We recently demonstrated that the
urinary measurement of MCP-1, a chemokine produced by
infiltrating monocytes, correlates with the severity of the
renal damage [81]. My question is, do you know of other
serum or urinary mediators that clinicians can measure to
follow patients affected by mixed cryoglobulinemia and
renal lesions and to evaluate the effectiveness of the
treatment used?
DR. D’AMICO: The relationship between cryocrit and
prognosis of renal disease is still a matter of debate. In the
retrospective analysis of the Milano experience, Tarantino
et al found the level of circulating cryoglobulins to be a
significant indicator of an unfavorable prognosis in the
univariate, but not the multivariate, analysis [31]. This
finding means that the cryocrit has some prognostic value,
although not a strong one. Indeed, complications can occur
without an increase of cryocrit, but if you monitor the level
of circulating cryoglobulins in a patient with a high cryocrit
at the start of treatment, you always find a reduction of this
level if there is a therapeutic effect. In this circumstance,
the level of cryoglobulins, and in case you are using IFNa,
the disappearance of HCV RNA from the serum, are two
good parameters for monitoring the disease. This is not the
case for serum C4, which remains low, regardless of the
course of the disease, although in some cases you can find
a higher level of C4 during stages of quiescence. The
behavior of serum C3 is unpredictable. Frequently, flares
are characterized by a reduction of the level of C3, which
heralds new disease activity despite the persistently de-
pressed C4 level.
DR. CLAUDIO PONTICELLI (Head, Division of Nephrology,
Ospedale Maggiore, Milano): Interferon therapy certainly
has a rationale in the treatment of patients with mixed
cryoglobulinemia. However, I would suggest a word of
caution in patients with renal involvement. It is well known
that IFNa can cause proteinuria and also a mild increase in
serum creatinine in patients without renal disease. More-
over, several cases of nephrotic syndrome and acute renal
failure also have been reported [82]. The risk of renal
function deterioration might be increased in patients with
renal disease. In our own experience, severe renal exacer-
bation occurred in 2 of 5 patients treated with IFNa
because of cryoglobulinemic nephritis.
I have a question about the treatment of disease flares. I
fully agree that methylprednisolone pulse therapy is the
treatment of choice. In our hands, it has proved quite
effective: renal function improved in approximately 90% of
patients treated because of a rapid increase in plasma
creatinine. This rate is better than the 48% response
reported in the literature with the use of oral corticoste-
roids or other immunosuppressive drugs [83]. However, if
we follow the strategy of aggressively treating the disease
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exacerbations while withholding steroids and other immu-
nosuppressive agents in the quiescent periods, we need a
strict definition of disease flare to avoid over- or under-
immunosuppression. What clinical criteria do you use for
diagnosing and treating acute exacerbations of cryoglobu-
linemic glomerulonephritis?
DR. D’AMICO: I agree with the policy of restricting
therapy to the acute stages of the renal disease, using only
antihypertensive treatment during the quiescent phase.
Many of our patients have never been treated with IFNa,
because we use it during disease flares to control the
possible deleterious effects of the concomitant immunosup-
pressive treatment. As for a strict definition of disease flare,
I must confess that it’s a complex problem. When renal
function deteriorates rapidly, especially in the company of
purpura or suspected mesenteric vasculitis (very severe
abdominal pain), one can be confident of a renal flare and
can start aggressive treatment even without a renal biopsy.
Even a less severe but rather rapid deterioration of renal
function, as in Patient 2 (the serum creatinine was only 2.5
mg/dl, but it had been increasing rapidly while the protein-
uria had reached the nephrotic range) suggests an acute
flare. Obviously, if biopsy material is available, a flare can
be recognized from its characteristic features (first biopsies
of Patients 1 and 2): massive infiltration of glomeruli with
monocytes, which is probably responsible for the rapid
increase in proteinuria; intraluminal thrombi, that is, the
massive precipitation of circulating cryoglobulins; or active
vasculitic lesions. However, you will recall that we consid-
ered a flare even the histologic picture found in Patient 3:
in this patient, the morphologic features of a lobular GN
could not be considered per se a sign of very active disease,
but the clinical signs—increase in proteinuria and serum
creatinine after a very long history of mild renal involve-
ment—led us to initiate aggressive treatment, which in-
duced rapid normalization of the serum creatinine and
reduction of proteinuria along with remission of purpura
and arthralgias. I want to emphasize that in HCV-associ-
ated cryoglobulinemic GN, as in lupus nephritis and all
systemic diseases, the diagnosis of disease flare cannot be
based exclusively on the renal signs but must take into
consideration all associated signs and symptoms.
DR. GIUSEPPE PICCOLI (Director, Institute of Nephrology,
University of Turin, Turin, Italy): The patients presented by
Prof. D’Amico stress the importance of the nephrotic
syndrome in the presence of renal failure as the most
relevant renal clinical presentation. However, I would like
to draw your attention to the subset of patients with minor
signs of renal disease, microscopic hematuria or subne-
phrotic proteinuria. In these patients, a renal biopsy might
show significant proliferative lesions. This clinicopathologic
dissociation might not last forever, and a further subset of
cases might progress toward nephrotic syndrome or renal
failure. On this basis, I believe that all HCV-positive
patients with cryoglobulinemia who have even minor signs
of renal involvement should undergo a renal biopsy, obvi-
ously in the absence of contraindications to biopsy. What is
your opinion?
DR. D’AMICO: I completely agree with you, Beppe. We
have seen many patients with minor systemic clinical signs,
normal renal function, and only minor abnormalities in the
urine, who at biopsy showed very severe infiltrations of
monocytes and sometimes also signs of vasculitis. This
finding means that the clinical picture is not always suffi-
cient for deciding the therapeutic approach, and that the
biopsy, in the absence of contraindications, is often useful.
If we find what we consider “severe” lesions, we start the
aggressive treatment that I have discussed. In the presence
of features of mild mesangial proliferation, with moderate
or absent macrophage infiltration, we only use antihyper-
tensive drugs, preferentially including ACE inhibitors.
DR. GIORGIO FUIANO (Director, Institute of Nephrology,
University of Catanzaro, Catanzaro, Italy): Ribavirin has
been shown to be effective in hepatitis C and has fewer side
effects than IFNa. What do you think about clinical trials of
ribavirin in mixed cryoglobulinemia?
DR. D’AMICO: We didn’t consider the use of ribavirin in
our trial because, as you know, this drug is not available yet
in our country, and because we preferred to investigate the
clinical efficacy of more frequently administered (daily)
doses of IFNa. It is possible that the combination of IFNa
with ribavirin will become a common type of therapy before
our trial is completed if the preliminary data on ribavirin’s
efficacy are confirmed.
DR. DARIO ROCCATELLO (Division of Nephrology, G.
Bosco Hospital, Turin): As you emphasized, phagocytic cells
loaded with cryoglobulins are common findings on electron
microscopic examination of these patients’ biopsy specimens.
Nevertheless, the processing of phagocytosed cryoglobulins is
probably delayed, and severe monocyte/macrophage dysfunc-
tion has been well established in cryoglobulinemia, includ-
ing impaired hepatosplenic elimination of circulating cryo-
globulins, increased propensity to release extracellularly
lytic pro-enzymes, and increased production of cytokine
precursor forms in cultured monocytes exposed to cryo-
globulins [84]. In my opinion, these cells are not predomi-
nantly activated or defective; they simply are functionally
deranged. Monocytes from HCV-positive patients had def-
inite abnormalities as well [84]. The lymphotropic nature of
HCV could induce a derangement of autoantibody synthe-
sis, exemplified by monoclonal IgM production with RF
activity, but the phagocytic cells themselves could be in-
fected with HCV; thus the reticulophagocytic system might
become less effective in processing circulating cryoglobu-
lins, favoring a greater impact of cryoglobulins on glomer-
uli. Would you comment on this possibility?
DR. D’AMICO: I must apologize because I did not have
the time to discuss your interesting studies in my presenta-
tion. Looking at the cryoglobulinemic patients, I think that
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the overload of monocytes from phagocytosed cryoglobu-
lins can derange them functionally and can lead to the
persistent presence of cryoglobulin deposits and of mono-
cytes in the glomerulus. However, not all cases feature such
an impaired function of monocytes/macrophages. We have
witnessed on at least two occasions a very rapid disappear-
ance of massive intraluminal deposits of cryoglobulins in
patients with acute renal failure who were not treated at all
because of delayed referral.
DR. ROSANNA COPPO (Head, Division of Pediatric Nephrol-
ogy, Regina Elena Hospital, Turin): One of the most distinc-
tive serologic hallmarks of cryoglobulinemic glomerulone-
phritis is the very low level of C4, usually lower than that
seen in lupus nephritis. The high levels of complement
breakdown products, including C3A and C5A, suggest that
the presence of C4-binding protein in patients with cryo-
globulinemic GN leads to continuous activation of the C3
convertase pathway. Does this continuous activation of the
complement system contribute to leukocyte chemotaxis and
renal damage in cryoglobulinemic GN?
DR. D’AMICO: I am amazed that so few studies have been
carried out in the last 15 years on the role of complement
in this disease, despite the very distinctive pattern that
should attract the interest of experts in the field. However,
after Gigli et al demonstrated the alteration of the C4-
binding protein [34], no other relevant studies have been
published to my knowledge.
DR. ANTONIO TARANTINO (Division of Nephrology, Osped-
ale Maggiore, Milano): Patients with mixed cryoglobuline-
mia who require renal replacement therapy evidence re-
duction in the clinical manifestations of the underlying
disease. Could you speculate about the responsible mech-
anisms? Also, you suggested that a specific affinity of IgMk
RF for cellular fibronectin, a constituent of mesangial
matrix, is responsible for the glomerular deposition of
circulating cryoglobulins. We know that the main charac-
teristic of immune complexes in mixed cryoglobulinemia is
their cryoprecipitability, which depends on the peculiar
reactivity of IgMk against the polyclonal IgG and on their
intrinsic physicochemical properties. Indeed, in experimen-
tal models, Gyotoku et al [85] and Reininger et al [86]
reported that the injection in normal mice of a cryoprecipi-
tating murine RF could induce both vasculitis and glomer-
ulonephritis. This work suggests that both RF activity and
cryoprecipitability are essential for development of vascu-
litis and GN. Could the cryoprecipitation phenomenon be
a contributing factor for the deposition of immune reac-
tants, at least in patients showing extensive intraluminal
thrombi in glomerular capillaries?
DR. D’AMICO: Just as in patients with lupus nephritis
reaching end-stage renal failure, patients with mixed cryo-
globulinemia exhibit reduced systemic signs of the disease
during regular dialysis. The explanation might lie with the
immunosuppressive effect of uremia. As for your second
question, I think that cryoprecipitability is particularly
important for generating damage at the renal level. The
experiment by Gyotoku et al that you quoted has been
repeated by Lemoine and colleagues [87]. These investiga-
tors tried to separate the cryoprecipitating activity from the
RF activity using a hybrid antibody possessing only the
cryoprecipitable activity and not the RF activity; nonethe-
less, the glomerular lesions obtained in mice were similar to
those that had been obtained by them and by Gyotoku
when an antibody sharing both activities had been used [85,
87]. I think that our experiments on affinity of RFs for
fibronectin demonstrate the same fact: only the RF isolated
from cryoprecipitable type-II MC had specific affinity; all
the other monoclonal RFs were not able to fix fibronectin
[58].
Reprint requests to Prof. Giuseppe D’Amico; Division of Nephrology; San
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